168 related articles for article (PubMed ID: 38225189)
1. Research Progress on Structure-Activity Relationship of 1,8-Naphthalimide DNA Chimeras Against Tumor.
Zhang HY; Han LL; Wu HY; Xu XX; Yu MB; Chen GY; Qi XL
Technol Cancer Res Treat; 2024; 23():15330338231225861. PubMed ID: 38225189
[TBL] [Abstract][Full Text] [Related]
2. 1,8-Naphthalimide: A Potent DNA Intercalator and Target for Cancer Therapy.
Tandon R; Luxami V; Kaur H; Tandon N; Paul K
Chem Rec; 2017 Oct; 17(10):956-993. PubMed ID: 28375569
[TBL] [Abstract][Full Text] [Related]
3. Naphthalimides and azonafides as promising anti-cancer agents.
Ingrassia L; Lefranc F; Kiss R; Mijatovic T
Curr Med Chem; 2009; 16(10):1192-213. PubMed ID: 19355879
[TBL] [Abstract][Full Text] [Related]
4. Anticancer Activity and Topoisomerase II Inhibition of Naphthalimides with ω-Hydroxylalkylamine Side-Chains of Different Lengths.
Tomczyk MD; Byczek-Wyrostek A; Strama K; Wawszków M; Kasprzycki P; Walczak KZ
Med Chem; 2019; 15(5):550-560. PubMed ID: 30207241
[TBL] [Abstract][Full Text] [Related]
5. Recent developments on 1,8-Naphthalimide moiety as potential target for anticancer agents.
Tandon R; Luxami V; Tandon N; Paul K
Bioorg Chem; 2022 Apr; 121():105677. PubMed ID: 35202852
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, electrochemistry, DNA binding and in vitro cytotoxic activity of tripodal ferrocenyl bis-naphthalimide derivatives.
Fan YR; Wang BJ; Jia DG; Yang XB; Huang Y
J Inorg Biochem; 2021 Jun; 219():111425. PubMed ID: 33831713
[TBL] [Abstract][Full Text] [Related]
7. Naphthalimide derivatives with therapeutic characteristics: a patent review.
Kamal A; Bolla NR; Srikanth PS; Srivastava AK
Expert Opin Ther Pat; 2013 Mar; 23(3):299-317. PubMed ID: 23369185
[TBL] [Abstract][Full Text] [Related]
8. Effect of intercalator substituent and nucleotide sequence on the stability of DNA- and RNA-naphthalimide complexes.
Johnson CA; Hudson GA; Hardebeck LK; Jolley EA; Ren Y; Lewis M; Znosko BM
Bioorg Med Chem; 2015 Jul; 23(13):3586-91. PubMed ID: 25960324
[TBL] [Abstract][Full Text] [Related]
9. Synthesis of naphthalimide-phenanthro[9,10-d]imidazole derivatives: In vitro evaluation, binding interaction with DNA and topoisomerase inhibition.
Singh I; Luxami V; Paul K
Bioorg Chem; 2020 Mar; 96():103631. PubMed ID: 32036164
[TBL] [Abstract][Full Text] [Related]
10. Synthesis of naphthalimide-carborane and metallacarborane conjugates: Anticancer activity, DNA binding ability.
Nekvinda J; Różycka D; Rykowski S; Wyszko E; Fedoruk-Wyszomirska A; Gurda D; Orlicka-Płocka M; Giel-Pietraszuk M; Kiliszek A; Rypniewski W; Bachorz R; Wojcieszak J; Grüner B; Olejniczak AB
Bioorg Chem; 2020 Jan; 94():103432. PubMed ID: 31776032
[TBL] [Abstract][Full Text] [Related]
11. Synthesis of novel C4-benzazole naphthalimide derivatives with potent anti-tumor properties against murine melanoma.
Lu YT; Chen TL; Chang KS; Chang CM; Wei TY; Liu JW; Hsiao CA; Shih TL
Bioorg Med Chem; 2017 Jan; 25(2):789-794. PubMed ID: 27939348
[TBL] [Abstract][Full Text] [Related]
12. Heterocyclic Naphthalimides as New Skeleton Structure of Compounds with Increasingly Expanding Relational Medicinal Applications.
Gong HH; Addla D; Lv JS; Zhou CH
Curr Top Med Chem; 2016; 16(28):3303-3364. PubMed ID: 27150364
[TBL] [Abstract][Full Text] [Related]
13. An Outlook of the Structure Activity Relationship (SAR) of Naphthalimide Derivatives as Anticancer Agents.
Bhat AA
Anticancer Agents Med Chem; 2024; 24(2):96-116. PubMed ID: 37974443
[TBL] [Abstract][Full Text] [Related]
14. l,8-Naphthalimide based DNA intercalators and anticancer agents. A systematic review from 2007 to 2017.
Tomczyk MD; Walczak KZ
Eur J Med Chem; 2018 Nov; 159():393-422. PubMed ID: 30312931
[TBL] [Abstract][Full Text] [Related]
15. A new class of naphthalimide-based antitumor agents that inhibit topoisomerase II and induce lysosomal membrane permeabilization and apoptosis.
Chen Z; Liang X; Zhang H; Xie H; Liu J; Xu Y; Zhu W; Wang Y; Wang X; Tan S; Kuang D; Qian X
J Med Chem; 2010 Mar; 53(6):2589-600. PubMed ID: 20170164
[TBL] [Abstract][Full Text] [Related]
16. Molecular design, chemical synthesis, and biological evaluation of '4-1' pentacyclic aryl/heteroaryl-imidazonaphthalimides.
Li F; Cui J; Guo L; Qian X; Ren W; Wang K; Liu F
Bioorg Med Chem; 2007 Aug; 15(15):5114-21. PubMed ID: 17532640
[TBL] [Abstract][Full Text] [Related]
17. Remarkable DNA binding affinity and potential anticancer activity of pyrrolo[2,1-c][1,4]benzodiazepine-naphthalimide conjugates linked through piperazine side-armed alkane spacers.
Kamal A; Ramu R; Tekumalla V; Khanna GB; Barkume MS; Juvekar AS; Zingde SM
Bioorg Med Chem; 2008 Aug; 16(15):7218-24. PubMed ID: 18656370
[TBL] [Abstract][Full Text] [Related]
18. DNA binding and anticancer activity of naphthalimides with 4-hydroxyl-alkylamine side chains at different lengths.
Wang K; Wang Y; Yan X; Chen H; Ma G; Zhang P; Li J; Li X; Zhang J
Bioorg Med Chem Lett; 2012 Jan; 22(2):937-41. PubMed ID: 22200595
[TBL] [Abstract][Full Text] [Related]
19. Design, Synthesis, and Evaluation of Novel 3-Carboranyl-1,8-Naphthalimide Derivatives as Potential Anticancer Agents.
Rykowski S; Gurda-Woźna D; Orlicka-Płocka M; Fedoruk-Wyszomirska A; Giel-Pietraszuk M; Wyszko E; Kowalczyk A; Stączek P; Bak A; Kiliszek A; Rypniewski W; Olejniczak AB
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33803403
[TBL] [Abstract][Full Text] [Related]
20. 5-Non-amino aromatic substituted naphthalimides as potential antitumor agents: Synthesis via Suzuki reaction, antiproliferative activity, and DNA-binding behavior.
Xie L; Cui J; Qian X; Xu Y; Liu J; Xu R
Bioorg Med Chem; 2011 Jan; 19(2):961-7. PubMed ID: 21208805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
